NCT01402245

Targeting of Immune Response After Pneumococcal Vaccination

Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Helsinki University Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Detailed description

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Conditions

• Pneumococcal Pneumonia

Interventions

Type	Name	Description
BIOLOGICAL	Pneumococcal polysaccharide vaccine	Pneumococcal polysaccharide vaccine 0.5 ml i.m.
BIOLOGICAL	pneumococcal conjugate vaccine	pneumococcal conjugate vaccine 0.5 ml i.m.

Timeline

• Start date: 2005-01-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2011-07-26
• Last updated: 2011-07-26

Locations

4 sites across 1 country: Finland